Akèy › Distrofi myotonik
Etid klinik pou Distrofi myotonik ap rekrite nan Etazini
19 etid pou Distrofi myotonik ap rekrite patisipan nan sit atravè Etazini.
Vil ki gen plis etid
- Richmond, VA8 etid
- Rochester, NY7 etid
- Boston, MA4 etid
- Los Angeles, CA4 etid
- Gainesville, FL3 etid
- Cedar Rapids, IA3 etid
Pa eta
- Florid3 etid
- Iowa3 etid
- Kalifòni5 etid
- Kansas4 etid
- Massachusetts4 etid
- New York8 etid
- North Carolina4 etid
- Pennsylvania3 etid
- Texas3 etid
- Virginia8 etid
Etid ki fèk mete ajou
Tèks ofisyèl etid la (Anglè)
Efficacy, Safety, and Tolerability of Zeleciment Basivarsen (DYNE-101) in Participants With Myotonic Dystrophy Type 1
Ap rekriteFaz 3
Laj 16 ak plis · Tout sèks · Mizajou Sep 25, 2026 · NCT07486934A Study to Investigate the Safety, Tolerability, and Efficacy of SAR446268, an Adeno-associated Viral Vector-mediated Gene Therapy in Participants Aged 10 to 55 Years of Age With Non-congenital Myotonic Dystrophy Type 1
Ap rekriteFaz 1/2
Laj 10 a 55 · Tout sèks · Mizajou Sep 21, 2026 · NCT06844214Establishing Biomarkers and Clinical Endpoints in Myotonic Dystrophy Type 1 (END-DM1) Extension
Ap rekriteEtid obsèvasyon
Laj 18 a 70 · Tout sèks · Mizajou Sep 4, 2026 · NCT07700225Trial Readiness and Endpoint Assessment in Pediatric Myotonic Dystrophy Extension
Ap rekriteEtid obsèvasyon
Laj 3 a 17 · Tout sèks · Mizajou Aug 11, 2026 · NCT06747884Estab Biomarkers and Clinical Endpoints in Myotonic Dystrophy Type 1 (END-DM1)
Ap rekriteEtid obsèvasyon
Laj 18 a 70 · Tout sèks · Mizajou Jun 10, 2026 · NCT03981575DMCRN-02-001: Assessing Pediatric Endpoints in DM1
Ap rekriteEtid obsèvasyon
59 Months · Tout sèks · Mizajou Jun 10, 2026 · NCT05224778Remote Assessments and Genetic Determinants of Congenital and Childhood Myotonic Dystrophy
Ap rekriteEtid obsèvasyon
Laj 0 a 17 · Tout sèks · Mizajou Jun 5, 2026 · NCT07630389Efficacy, Safety, and Tolerability of Zeleciment Rostudirsen (DYNE-251) Administered Intravenously Every 4 Weeks in Ambulatory Participants With Duchenne Muscular Dystrophy (FORZETTO)
Ap rekriteFaz 3
Laj 4 a 18 · Gason · Mizajou May 27, 2026 · NCT07608432Investigating Exercise in Myotonic Dystrophy Type 2 (DM2)
Ap rekrite
Laj 18 a 70 · Tout sèks · Mizajou Apr 15, 2026 · NCT06716931Remote Assessments and Genetic Determinants of Myotonic Dystrophy
Ap rekriteEtid obsèvasyon
Laj 18 a 88 · Tout sèks · Mizajou Apr 1, 2026 · NCT07505342Study of ATX-01 in Participants With DM1
Ap rekriteFaz 1/2
Laj 18 a 64 · Tout sèks · Mizajou Feb 10, 2026 · NCT06300307Development of Quantitative Muscle Imaging as a Biomarker of Disease Endpoints in Myotonic Dystrophy
Ap rekriteEtid obsèvasyonVolontè an sante akeyi
Laj 18 a 65 · Tout sèks · Mizajou Jan 23, 2026 · NCT07362875Biomarker Development for Muscular Dystrophies
Ap rekriteEtid obsèvasyonVolontè an sante akeyi
Laj 5 ak plis · Tout sèks · Mizajou Nov 24, 2025 · NCT05019625Cerebrospinal Fluid Biomarkers of Myotonic Dystrophy
Ap rekriteEtid obsèvasyon
Laj 18 ak plis · Tout sèks · Mizajou Nov 24, 2025 · NCT06075693Extracellular RNA Biomarkers of Myotonic Dystrophy
Ap rekriteEtid obsèvasyonVolontè an sante akeyi
Laj 5 ak plis · Tout sèks · Mizajou Nov 24, 2025 · NCT05020002Long-Term Development of Muscular Dystrophy Outcome Assessments
Ap rekriteEtid obsèvasyon
Laj 6 a 50 · Tout sèks · Mizajou Nov 18, 2025 · NCT05989620Myotonic Dystrophy and Facioscapulohumeral Muscular Dystrophy Registry
Ap rekriteEtid obsèvasyonVolontè an sante akeyi
Tout laj · Tout sèks · Mizajou Oct 15, 2025 · NCT00082108Safety and Efficacy of Tideglusib in Congenital or Childhood Onset Myotonic Dystrophy
Ap rekriteFaz 2/3
Laj 6 a 45 · Tout sèks · Mizajou May 28, 2025 · NCT05004129Myotonic Dystrophy Family Registry
Ap rekriteEtid obsèvasyon
Tout laj · Tout sèks · Mizajou Nov 21, 2024 · NCT02398786Sous ClinicalTrials.gov, done yo ranmase Oct 1, 2026. Chak etid gen kritè li pou li menm; ekip etid la deside ki moun ki ka patisipe.